Low Incidence of Neuroleptic Malignant Syndrome Associated With Paliperidone Palmitate Long-Acting Injectable: A Database Report and Case Study

To the Editors:

Neuroleptic malignant syndrome (NMS) is a rare, potentially fatal, and idiosyncratic adverse reaction that occurs in approximately 0% to 3% of individuals taking conventional antipsychotic medication. This syndrome usually presents with rigidity, abrupt onset of fever, autonomic dysregulation, and altered mental status. Other symptoms associated with NMS include tremor, extrapyramidal symptoms, altered electrocardiogram, and laboratory abnormalities, such as elevated serum creatine kinase (CK), impaired liver function tests, leukocytosis, electrolyte abnormalities, renal impairment, and altered coagulation (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition criteria for NMS). The primary cause of NMS is thought to be dopamine receptor blockade, particularly with the use of antipsychotic medications.

Available evidence of NMS associated with oral antipsychotics suggests that second-generation oral antipsychotics have a lower incidence of NMS, with less severity and infrequent fatal outcomes, compared with first-generation oral antipsychotics. In contrast, little is known about the frequency and management of NMS associated with long-acting injectables (LAIs) prescribed for treatment of schizophrenia, including LAIs of paliperidone (9-OH metabolite of risperidone) such as paliperidone palmitate 1-monthly (PP1M) and 3-monthly (PP3M). The concern about NMS being underutilized because of the perception that an LAI antipsychotic is not quickly cleared from the patient’s system and may hinder NMS management. This letter discusses the incidence and nature of NMS associated with paliperidone palmitate LAI formulations identified from Janssen clinical trial databases of PP1M and PP3M and the treatment implications for NMS associated with second-generation antipsychotic LAI formulations.

All cases of NMS in the Janssen PP1M and PP3M phases 1 to 3 clinical trial databases were searched cumulatively through April 30, 2018. Specific Medical Dictionary for Regulatory Activities (MedDRA, version 16.0) preferred terms used in the search for NMS are listed in Table 1. Individual case review was performed for each patient who experienced at least one of the terms listed. In each identified case, reports of treatment-emergent adverse events, vital signs, physical examination, laboratory findings, and clinical management of the event were reviewed. The incidence rate of NMS was calculated based on the number of identified cases divided by the total person-time at risk.

The Janssen clinical trial database search identified 1 credible case of NMS from 5008 patients who received 1 or more injection of PP1M or PP3M and were followed for 2271.6 patient-years. A second case of NMS was identified but was not included in this study because the patient (from a single-dose pharmacokinetics study in Japan; NCT01606254) was diagnosed with NMS more than 3 months (approximately 3 half-lives) after the last injection of PP1M. Furthermore, the patient was receiving other antipsychotics at the time of injection of PP1M. The resulting raw incidence of NMS was 0.020% (95% confidence rate 0.000% to 0.047%).

**Table 1. List of Preferred Terms Used in the Search for NMS in the Janssen Clinical Trial Database**

| Preferred terms used were from Medical Dictionary for Regulatory Activities (MedDRA, version 16.0). | }
CASE REPORT
The patient identified with NMS was a 55-year-old, white man with a diagnosis of schizophrenia, paranoid type, since 17 years of age who was enrolled in a randomized, double-blind, parallel-group study of flexibly dosed PP1M versus Risperdal CONSTA (Risperidone LAI).10 The patient had 4 prior hospitalizations for psychosis and a history of smoking, had no alcohol or drug abuse, and had no other significant medical history reported. The physical examination at screening was unremarkable, except for reduced hearing in the left ear, cerumen in both ear canals, gum disease, cavities, and a body mass index of 25.7 kg/m² (overweight). The patient was previously treated with fluphenilxol decanoate 15 mg intramuscularly every 2 weeks for 6 years, which was discontinued 22 days prior to randomization. From day –6 to day –3 of the screening period, the patient was given paliperidone extended release 3 mg for oral tolerability testing. On days 1 and 8 of the double-blind period, the patient received an injection of 50 mg eq PP1M in the gluteal muscle. A predose pharmacokinetic plasma sample was collected on day 1, and paliperidone levels were below the limit of quantification.

On day 15, the patient was hospitalized for confused mental state and had experienced a fever (38.8°C) and little rigidity and had “trouble relaxing” his muscles. The diagnosis of mild NMS was made, and laboratory results showed elevated levels of CK (5824 U/L [reference range, 55–197 U/L]) and hepatic enzymes, including aspartate transaminase (128 U/L [reference range, 12–45 U/L]) and alanine transaminase (91 U/L [reference range, 7–40 U/L]). Blood pressure and pulse rate were normal.

On day 16, lorazepam 0.5 to 1 mg/d as a rescue medication was initiated and continued as needed for 2 days, and ciprofloxacin 500 mg twice daily for 6 days was given for suspected infection that was later ruled out. Treatment with PP1M was discontinued on day 19 (last dose was on day 8), and the patient was withdrawn from the study because of the serious treatment-emergent adverse event of NMS. On day 20, the CK level was 860 U/L, alanine transaminase was 91 U/L, and aspartate transaminase was 49 U/L. Benztrapine 1 to 2 mg/d was given from days 19 to 26, then the dose was tapered and discontinued over 2 days. Fluphenilxol decanoate 15 mg intramuscularly every 2 weeks was resumed on day 23. The pyrexia was treated with acetaminophen as needed. No additional treatment was given for dizziness, psychiatric disorder, elevated liver enzymes, or elevated CK levels. On day 28, the patient went on a “leave of absence” from the hospital as he was reported to have done reasonably well but returned to the hospital on day 34 after feeling unwell, with disorientation. The patient had fever of 38.5°C on day 34, but his temperature soon returned to normal (patient’s home was not air conditioned, and the city of residence was warm at that time). After all investigations were normal, the patient went on a second leave of absence from days 36 to 46. The patient was discharged from the hospital on day 46 following complete recovery.

DISCUSSION
From data of 5008 patients analyzed in the Janssen clinical trial database for NMS with PP1M and PP3M, a single case of NMS associated with PP1M LAI was identified. The most common manifestations of NMS, including altered mental state, muscle rigidity, fever, and elevated CK (>1000 U/L), were reported in this case. The severity of NMS appeared to be mild, and the patient recovered completely. This database review illustrates the low propensity for NMS events during PP1M or PP3M treatment and successful management of this complication in the single case identified with symptomatic treatment.

Given that NMS is a known and rare adverse event associated with use of antipsychotics, the investigator judged that the etiology of NMS was possibly related to PP1M. However, the patient was also receiving fluphenilxol decanoate 15 mg intramuscularly every 2 weeks (variable half-life between 3 weeks and 3 months) for 6 years prior to randomization, which was discontinued 22 days before PP1M administration. Thus, it is possible that initiation of NMS on day 15 cannot be attributed solely to PP1M, but rather could be related to a combined effect of both LAI antipsychotic agents (fluphenilxol decanoate and PP1M). Also, worsening of symptoms on day 34 could likely be related to the fluphenilxol depot given on day 23, further supporting the additive effect of the 2 drugs. Findings from a retrospective study also showed that the use of depot fluphenilxol was significantly associated with increased risk of NMS.11 In the present case, oral tolerability medication (paliperidone extended release), although below limit of quantification at baseline, may also be a contributory factor.

Potential limitations of this study include possible underreporting of adverse drug reaction, inadequate sensitivity of the search method, and relatively short follow-up time of patients (on average, ~5.4 months).

ACKNOWLEDGMENTS
Ramji Narayanan, ISMPP CMPP (SIBO Clinpharm Pvt. Ltd., India) provided writing assistance, funded by Janssen Global Services, LLC, and Ellen Baum, PhD (Janssen Global Services, LLC) provided additional editorial support for the development of this manuscript.

AUTHOR DISCLOSURE INFORMATION
S.G., A.S., M.M. are employees of Janssen Research & Development, LLC, and hold company stock. J.M.K. has been a consultant and/or advisor to and/or has received honoraria from Allergan, Bristol-Myers Squibb, IntraCellular Therapies, Janssen, Lundbeck, Minerva, Neurocrine, Otsuka, Pierre Fabre, Reviva, Sunovion, Takeda, and Teva and is a shareholder of LB Pharma, MedAvante, and The Vanguard Research Group. C.U.C. has been a consultant and/or advisor to or has received honoraria from Alkermes, Allergan, Angelini, Gerson Lehrman Group, IntraCellular Therapies, Janssen/J&J, LB Pharma, Lundbeck, MedAvante, Medscape, Merck, Neurocrine, Otsuka, Pfizer, ROVI, Servier, Sunovion, Takeda, and Teva. He has provided expert testimony for Bristol-Myers Squibb, Janssen, and Otsuka. He served on a Data Safety Monitoring Board for Lundbeck, ROVI, and Teva. He received royalties from UpToDate and grant support from Janssen and Takeda. He is also a shareholder of LB Pharma. N.D. has participated as an investigator in clinical studies and has no other potential conflict of interest to declare.

Registration: ClinicalTrial.gov NCT00210717.
Poster presented at 30th Annual US Psych Congress, September 16 to 19, 2017, New Orleans, LA.
Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Letters to the Editors

Journal of Clinical Psychopharmacology • Volume 39, Number 2, March/April 2019

John M. Kane, MD
The Zucker Hillside Hospital
Glen Oaks, NY
The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Glen Oaks, NY
JKane2@northwell.edu

Chrstoph U. Correll, MD
The Zucker Hillside Hospital
Glen Oaks, NY
The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Glen Oaks, NY
and Department of Child and Adolescent Psychiatry
Charité Universitätsmedizin
Berlin, Germany

Nicholas Delva, MD
Providence Care Hospital
Kingston, Ontario, Canada

Srihari Gopal, MD, MHS
Adam Savitz, MD, PhD
Maju Mathews, MD
Janssen Research & Development LLC, Raritan, NJ

To the Editors:

Effects of Curcumin on Cognitive Functioning and Inflammatory State in Schizophrenia
A Double-Blind, Placebo-Controlled Pilot Trial

Curcumin, derived from turmeric root, is a polyphenol with antioxidant and anti-inflammatory properties.1–2 To our knowledge, only 2 studies have tested the effectiveness of add-on curcumin in patients with schizophrenia.2,3 In an open-label study, 1 g/d of curcumin (n = 7) and 4 g/d of curcumin (n = 8) improved overall neurocognitive index over 12 weeks. More recently, a randomized, double-blind, placebo-controlled study showed that 360 mg/d of curcumin (n = 17) increased brain-derived neurotrophic factor levels compared with placebo (n = 19) after an 8-week trial. Although this study did not show any significant changes in clinical symptoms and cognitive functioning, improvement on brain-derived neurotrophic factor levels suggested possible long-term benefits of curcumin in cognition and clinical symptoms.2,3

We tested the effects of add-on curcumin for the treatment of cognitive impairment in schizophrenia in an 8-week randomized, double-blind, placebo-controlled, parallel, fixed-dose pilot clinical trial. A total of 12 outpatients with schizophrenia were randomized to curcumin (180 mg/d) or placebo in a 1:1 ratio. Written informed consent was obtained from all participants. A commercially available surface-controlled water-soluble form of 300 mg of curcumin (30% formulation: 90 mg pure curcumin) or matching placebo capsules were provided by Theravales Corporation (Tokyo, Japan). Study protocol was approved by institutional review board (Yale HIC number 1412015121) and registered on ClinicalTrials.gov (NCT02476708). We monitored medication adherence by means of pill count method and patient reports.

The primary outcome measure was between-group changes in Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery.4 Secondary outcomes included changes in inflammatory markers (interleukin 6 [IL-6], tumor necrosis factor alpha, and high-sensitive C-reactive protein [hs-CRP]) and clinical outcomes (Positive and Negative Syndrome Scale [PANSS], Calgary Depression Scale for Schizophrenia, and The Committee of Clinical Investigations [UKI] side effect scale).

All statistical analyses were performed in SPSS Statistics version 24.0 (IBM, NY). Baseline differences and treatment effect in clinical symptoms, cognitive functioning, and inflammatory markers were assessed with nonparametric tests. Pearson χ2 analysis and Fisher exact tests were used for all categorical variables.

The study sample (9 male, 3 female) mostly consisted of chronic schizophrenia patients with mean ± SD duration of illness 21.66 ± 14.84 years (range, 5–51 years). Mean ± SD age of the total sample was 41.33 ± 12.73 years, and education level was 12.33 ± 2.42 years. At baseline, no significant difference was found in sample characteristics, inflammatory markers, and clinical outcomes between treatment arms. Table 1 summarizes changes in inflammatory markers, clinical outcomes, and cognitive functioning. Compared with placebo, add-on curcumin treatment significantly improved working memory (Z = 2.200, P = 0.028) and reduced IL-6 levels (Z = 2.402, P = 0.016). No significant effect of curcumin on PANSS and Calgary Depression scores was found. No significant adverse events were reported during the study. The majority of the patients reported that they took the medications as prescribed. Only 2 patients returned 10 capsules in total during the whole study period (4 curcumin and 6 placebo capsules).

In this pilot study, we found that add-on curcumin improved working memory in patients with schizophrenia. Add-on curcumin also reduced IL-6 levels after 8 weeks of treatment. Although improvements in other cognitive domains, negative symptoms, and total PANSS score were observed with add-on curcumin, these changes did not reach statistical significance.

To a degree, our findings are in line with previous studies. In an open-label study, Woodbury-Farina et al reported improved cognition and negative

REFERENCES

1. Ananth J, Paraneswaran S, Gunatilake S, et al. Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry. 2004;65:464–470.
2. Nielsen RE, Wallenstein Jensen SO, Nielsen J. Neuroleptic malignant syndrome–an 11-year longitudinal case-control study. Can J Psychiatry. 2012;57:512–518.
3. Gurrera RJ, Simpson JC, Tsuang MT. Meta-analytic evidence of systematic bias in estimates of neuroleptic malignant syndrome incidence. Compr Psychiatry. 2007;48:205–211.
4. Pelonero AL, Levenson JI, Pandurangki AK. Neuroleptic malignant syndrome: a review. Psychiatr Serv. 1998;49:1163–1172.
5. Brian DB. Neuroleptic malignant syndrome: a review for neurohospitalists. Neurohospitalist. 2011;1:41–47.
6. Belvederi Murri M, Guaglianone A, Bugliani M, et al. Second-generation antipsychotics and neuroleptic malignant syndrome: systematic review and case report analysis. Drugs R&D. 2015;15:45–62.
7. Sarkar S, Gupta N. Drug information update. Atypical antipsychotics and neuroleptic malignant syndrome: nuances and pragmatics of the association. Br J Psychiatry. 2017;211:216.
8. Farver DK. Neuroleptic malignant syndrome induced by atypical antipsychotics. Expert Opin Drug Saf. 2003;2:21–35.
9. Troughton JN, Chen X, Chitty K, et al. Comparison of neuroleptic malignant syndrome induced by first- and second-generation antipsychotics. Br J Psychiatry. 2012;201:52–56.
10. Fleischhacker WW, Gopal S, Lane R, et al. A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia. Int J Neuropsychopharmacol. 2012;15:107–118.
11. Su YP, Chang CK, Hayes RD, et al. Retrospective chart review on exposure to psychotropic medications associated with neuroleptic malignant syndrome. Acta Psychiatr Scand. 2014;130:52–60.

www.psychopharmacology.com